Meningitis vaccine approved for California college

Health officials at a Southern California college will start offering a vaccine against bacterial meningitis after an outbreak in November.

Officials at the University of California, Santa Barbara said Friday that federal health regulators have approved the vaccine for use on campus. The vaccine is approved for use overseas but is not yet approved for general use in the United States.

The move comes after Princeton University last year received permission to dole out the after eight students became infected.

Four students at Santa Barbara fell ill in November. Three recovered and the fourth had both feet amputated. No new cases have been diagnosed.

Meningococcal disease can be spread among people in dormitories and other crowded settings.

The university plans to hold a two-week vaccination clinic in late February.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Princeton vaccine reaches 90 percent of eligible

Dec 13, 2013

Princeton University officials say more than 90 percent of the eligible students and staff received a meningitis vaccine this week as part of the university's effort to halt an outbreak.

Recommended for you

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

FDA approves weight-loss drug Contrave (Update)

Sep 11, 2014

U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.

User comments